Trudhesa (dihydroergotamine mesylate intranasal) / Impel Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trudhesa (dihydroergotamine mesylate intranasal) / Impel Pharma
STOP-301, NCT03557333: Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Completed
3
360
US
INP104, Dihydroergotamine Mesylate (DHE) administered using the I123 Precision Olfactory Delivery (POD) Device, INP104, POD-DHE
Impel NeuroPharma Inc.
Migraine Headache
03/20
03/20

Download Options